Assure Tech (Hangzhou) Co Ltd is a biotechnology company. The company is engaged in research & development, production, sell of diagnostic reagents, POCT and biological materials.
2008
n/a
Last FY Revenue $75.0M
Last FY EBITDA $36.7M
$410M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Assure Tech achieved revenue of $75.0M and an EBITDA of $36.7M.
Assure Tech expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Assure Tech valuation multiples based on analyst estimatesNTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|
Revenue | XXX | $75.0M | XXX | XXX | XXX |
Gross Profit | XXX | $29.3M | XXX | XXX | XXX |
Gross Margin | XXX | 39% | XXX | XXX | XXX |
EBITDA | XXX | $36.7M | XXX | XXX | XXX |
EBITDA Margin | XXX | 49% | XXX | XXX | XXX |
EBIT | XXX | $1.1M | XXX | XXX | XXX |
EBIT Margin | XXX | 2% | XXX | XXX | XXX |
Net Profit | XXX | $26.7M | XXX | XXX | XXX |
Net Margin | XXX | 36% | XXX | XXX | XXX |
Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Assure Tech's stock price is CNY 38 (or $5).
Assure Tech has current market cap of CNY 4.8B (or $665M), and EV of CNY 3.0B (or $410M).
See Assure Tech trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$410M | $665M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Assure Tech has market cap of $665M and EV of $410M.
Assure Tech's trades at 5.5x EV/Revenue multiple, and 11.2x EV/EBITDA.
Equity research analysts estimate Assure Tech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Assure Tech's P/E ratio is not available.
See valuation multiples for Assure Tech and 12K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Market cap (current) | $665M | XXX | $665M | XXX | XXX | XXX |
EV (current) | $410M | XXX | $410M | XXX | XXX | XXX |
EV/Revenue | n/a | XXX | 5.5x | XXX | XXX | XXX |
EV/EBITDA | n/a | XXX | 11.2x | XXX | XXX | XXX |
EV/EBIT | n/a | XXX | 356.3x | XXX | XXX | XXX |
EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
P/E | n/a | XXX | 24.9x | XXX | XXX | XXX |
EV/FCF | n/a | XXX | -92.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialAssure Tech's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Assure Tech's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Assure Tech's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Assure Tech and other 12K+ public compsLTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
---|---|---|---|---|---|---|
Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | 49% | XXX | XXX | XXX |
EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
S&M Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
R&D Expenses to Revenue | XXX | XXX | 19% | XXX | XXX | XXX |
Opex to Revenue | XXX | XXX | 38% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
Healius | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Assure Tech acquired XXX companies to date.
Last acquisition by Assure Tech was XXXXXXXX, XXXXX XXXXX XXXXXX . Assure Tech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free TrialWhen was Assure Tech founded? | Assure Tech was founded in 2008. |
Where is Assure Tech headquartered? | Assure Tech is headquartered in China. |
Is Assure Tech publicy listed? | Yes, Assure Tech is a public company listed on SHG. |
What is the stock symbol of Assure Tech? | Assure Tech trades under 688075 ticker. |
When did Assure Tech go public? | Assure Tech went public in 2021. |
Who are competitors of Assure Tech? | Similar companies to Assure Tech include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
What is the current market cap of Assure Tech? | Assure Tech's current market cap is $665M |
Is Assure Tech profitable? | Yes, Assure Tech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.